MDS Pharma Services (Correction)
This article was originally published in The Pink Sheet Daily
FDA has recommended that MDS Pharma Services conduct an expanded review of bioequivalence studies conducted at the company's Montreal bioanalytical facility over the last five years
You may also be interested in...
A recent FDA inspection of MDS Pharma Services' Montreal bioanalytical facility has triggered an agency review of all bioequivalence studies conducted at the facility over the last five years. The contract research organization is reviewing its quality assurance practices.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.